iVIZIA | Eye Care Professionals

Covering the spectrum of

iVIZIA lubricant eye drops offer an advanced formulation and innovative bottle design in an over-the-counter (OTC) solution to provide relief for your patients who suffer from dry eyes.

Your patients will see the difference with preservative-free iVIZIA that delivers a comprehensive combination of lasting relief and ocular surface protection.^1-6

Advantages of iVIZIA Lubricant Eye Drops

iVIZIA lubricant eye drops are a preservative-free therapeutic advancement, combining the proven protective properties of trehalose with hyaluronic acid (HA) and povidone to offer extended relief to patients with any type of dry eye, including your patients who wear contact lenses.* Other than the inclusion of povidone, iVIZIA lubricant eye drops use the same formulation as Thealoz^® Duo, the #1 prescribed dry eye drops in Europe.^†

See the iVIZIA difference in ingredients, clinical evidence, and bottle design

See the difference in ingredients

iVIZIA is a comprehensive combination of ingredients specially formulated to target every point of the vicious dry eye circle.

Trehalose is a disaccharide demonstrated to provide ocular bioprotection, osmoprotection, and rehydration.^1-4

Studies show that trehalose enables cells to maintain viability, strengthening and improving tear film stability by:
- Regulating osmotic pressure with a hypotonic formulation designed to combat hyperosmolarity in the tear film
- Stabilizing the lipid bilayers
- Protecting proteins by preventing degeneration
- Maintaining homeostasis and reducing cell death

HA and povidone deliver lubrication with long-lasting relief.^5,6

HA is a naturally occurring glycosaminoglycan polysaccharide and a component of tear film with the ability to ^6-8:
- Lubricate—binding 1000× more water than its weight
- Protect the corneal epithelium with prolonged residence time and favorable rheologic properties
Povidone, the active ingredient, is a viscosity-enhancing agent beneficial to the ocular surface that provides moisturizing and lubricating properties

See the clinical evidence

Relative TFT over time (N=60) after instillation of unpreserved trehalose combined with HA (T-HA), unpreserved HA, or sodium chloride (NaCl). Data presented as mean ± SD.

†=Significant versus baseline for TH-HA.
‡=Significant versus baseline for HA.

The unique combination of 3% trehalose and 0.15% HA found in iVIZIA has been extensively studied and demonstrated effective in multiple independent clinical studies.

Trehalose and HA increased tear film thickness (TFT) for up to 240 minutes after a single administration compared to HA alone (N=60, P<0.0001)⁹
Improved the thickness of the tear film for at least 4 hours (6× longer than HA alone)⁹

Trehalose/HA combination efficacy demonstrated in multiple studies:

Decreased ocular surface inflammation, shown by a significant reduction of tear cytokines after 2 months compared to baseline with 1 drop TID (N=15, P<0.05)¹⁰
Provided a majority of patients with greater improvement in Ocular Surface Disease Index (OSDI) score compared with HA alone at day 84, the end of study (62% had an OSDI score of none at day 84 compared with 40%, respectively; P=0.044, N=105)³
Patients reported symptom relief with significant improvements in blurred vision, stinging, and itching (P<0.05, N=105)³

See the difference in bottle design

The iVIZIA bottle design uses the proprietary ABAK^™ technology to allow preservative-free, accurate-to-dose dry eye relief. It is the first easy-to-use multi-dose bottle, based on 10 years of research and development.

Multi-dose dispenser accurately delivers calibrated drops to eliminate streaming and waste and to make iVIZIA easy to use and cost-effective for patients
Patented filter membrane protects the solution from microbial contamination
In a multicenter study (N=654, n=448 >60 years of age), almost all patients preferred the ABAK bottle compared with other single-dose or multi-dose bottle delivery systems¹¹

This preservative free bottle is patented in US territory (US7971755, US9174777, US10857067 and US11116694)

Patients rate the iVIZIA-style, easy-squeeze ABAK bottle as

96.5%

easy to open

96.0%

easy to handle

91.1%

easy to get drops

See where iVIZIA product are available for your patients

*To limit blurriness when using contact lenses, remove contacts, apply drops, then insert contacts.
^†Source: Rx market data, Dec. 2022 - S01K without cyclosporine

Tackle the vicious circle of dry eye

Dry eye disease can be difficult to effectively treat, and it can be difficult to provide relief for your patients. It is a vicious circle with multiple entry points, but the combination of ingredients in iVIZIA lubricant eye drops can deliver much-needed relief to your patients.

The ingredients in iVIZIA target every entry point of the vicious dry eye circle with 4 actions that enable cells to maintain viability while strengthening the tear film and improving its stability:

Osmoregulation—allows the balance of the osmotic pressure on both sides of the cell membrane and thus limits the movement of water^4,12
- Hypotonic formulation designed to combat hyperosmolarity in the tear film
- Prevents water leakage from cytoplasm (osmoprotection)
Stabilizes lipid bilayers¹³
Protects proteins¹³
Prevents denaturation/degeneration of proteins¹³
Induces autophagy (recycling of cell materials) to maintain cell homeostasis and reduce apoptosis (cell death)^1,4

Help your patients see eye care differently

The iVIZIA portfolio of eye care products has been developed to offer advanced preservative-free solutions. When you recommend iVIZIA products to your patients, you can be confident that you are recommending a trusted combination of lasting relief and protection.

See what the comprehensive iVIZIA eye care product line offers

Dry Eye Products

iVIZIA Lubricant Eye Drops—a preservative-free formulation with the active ingredient povidone

Active ingredient enhanced by trehalose and hyaluronic acid (HA)
- Trehalose provides bioprotection, osmoprotection, and rehydration^1-4
- HA and povidone deliver lubrication with long-lasting relief ^5,6
Increased tear film thickness for up to 240 minutes⁹
Packaged in the proprietary ABAK^™ bottle—a multi-dose bottle capable of delivering calibrated eye drops
Suitable for all dry eye sufferers, including contact lens wearers*

Also available as a gel for severe and/or nighttime use

Eyelid Hygiene Products

iVIZIA Eyelid Cleansing Wipes—convenient daily cleansing for sensitive eyelids

No preservatives, parabens, soaps, or perfumes
Micellar formula gently breaks up and lifts lid oils and makeup
Ingredients include botanicals and zinc
No rinsing necessary after use
Clinically shown to reduce eyelid discomfort over time²³

iVIZIA Micellar Eyelid Cleanser—economical daily cleansing for eyelids

Liquid formulation with no BAK preservatives, parabens, soaps, or perfumes
Suitable for daily hygiene of eyelids, particularly at the base of the eyelashes
Micellar formula gently breaks up and lifts lid oils and makeup
No rinsing necessary after use

iVIZIA Eyelid Cleansing Gel—economical daily cleansing for sensitive eyelids

Preservative free, using proprietary Steri-Free Technology to protect gel from bacteria contamination after opening
Only 5 ingredients—each providing efficacy and safety to gently remove oils and makeup
Accurate and regular doses dispensed via the Mega Airless Pump
No rinsing necessary after use
Clinically shown to be a gentle and effective formula²⁴

*To limit blurriness when using contact lenses, remove contacts, apply drops, then insert contacts.

The iVIZIA Story

The iVIZIA commitment to advancing eye care dates back to the 19th century when the Chibret family in France—a family of ophthalmologists and inventors—strived to invent new and safe eye drops.

After its founding in 1994, Laboratoires Théa was among the first eye care companies to introduce preservative-free products, an accomplishment that to this day is unmatched by major competitors. Today, Laboratoires Théa continues its pursuit of solutions that are more efficacious, more ergonomic, and safer. By constantly innovating, Théa has become the market leader in dry eye treatments in Europe.*

Coming together to see a better way

In collaboration with Similasan, a Swiss-based leader in homeopathic OTC products with a focus on eye and ear products, Théa offers its technology and innovative preservative-free products to the US consumer under the iVIZIA brand of products—with iVIZIA lubricant eye drops as the foundation of the product line and formulated to cover the spectrum of dry eye relief.

Results from in vivo studies of iVIZIA and Thealoz^® Duo demonstrated the same rheological behaviors and pre-clinical effects between the two products. This means that iVIZIA, which is formulated with povidone, achieves the same results for patients as Thealoz Duo, the #1 prescribed dry eye drops in Europe.^25,*

* Source: Rx market data, Dec. 2022 - S01K without cyclosporine

Open your patients’ eyes to innovative eye care with iVIZIA

Offer relief to your patients who suffer from dry eyes—with iVIZIA lubricant eye drops.

Request samples of iVIZIA so you can recommend with confidence. Simply fill out the sample request form below, and samples will be on the way to your office.

References: 1. Chen W, Zhang X, Liu M, et al. Trehalose protects against ocular surface disorders in experimental murine dry eye through suppression of apoptosis. Exp Eye Res. 2009;89(3):311-318. 2. Aragona P, Colosi P, Rania L, et al. Protective effects of trehalose on the corneal epithelial cells. ScientificWorldJournal. 2014;2014:717835. 3. Chiambaretta F, Doan S, Labetoulle M, et al. A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome. Eur J Ophthalmol. 2017;27(1):1-9. 4. Liu Z, Chen D, Chen X, et al. Trehalose induces autophagy against inflammation by activating TFEB signaling pathway in human corneal epithelial cells exposed to hyperosmotic stress. Invest Ophthalmol Vis Sci. 2020;61(10):26. 5. US FDA Department of Health and Human Services. Ophthalmic drug products for over-the-counter human use. Updated October 21, 2021. Accessed January 19, 2022. https://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=349. 6. Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575-628. 7. Pisárčik M, Bakoš D, Čeppan M. Non-Newtonian properties of hyaluronic acid aqueous solution. Colloids Surf A Physicochem Eng Asp. 1995;97(3):197-202. 8. Rah MJ. A review of hyaluronan and its ophthalmic applications. Optometry. 2011;82(1):38-43. 9. Schmidl D, Schmetterer L, Witkowska KJ, et al. Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease. Cornea. 2015;34(4):421-6. 10. Fariselli C, Giannaccare G, Fresina M, Versura P. Trehalose/hyaluronate eyedrop effects on ocular surface inflammatory markers and mucin expression in dry eye patients. Clin Ophthalmol. 2018;12:1293-1300. 11. Gabisson P, Briat B, Le Foll J, et al. Handiness and acceptability of the new ABAK bottle in chronically treated patients. A cross-sectional, retrospective and multicentre study. Ann Pharm Fr. 2010;69(1):22-29. 12. Hovakimyan M, Ramoth T, Löbler M, et al. Evaluation of protective effects of trehalose on desiccation of epithelial cells in three dimensional reconstructed human corneal epithelium. Curr Eye Res. 2012;37(11):982-989. 13. Luyckx J, Baudouin C. Trehalose: an intriguing disaccharide with potential for medical application in ophthalmology. Clin Ophthalmol. 2011;5:577-581. 14. Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100(3):300-306. 15. Mochizuki H, Yamada M, Hato S, Nishida T. Fluorophotometric measurement of the precorneal residence time of topically applied hyaluronic acid. Br J Ophthalmol. 2008;92(1):108-111. 18. You IC, Li Y, Jin R, Ahn M, Choi W, Yoon KC. Comparison of 0.1%, 0.18%, and 0.3% Hyaluronic Acid Eye Drops in the Treatment of Experimental Dry Eye. J Ocul Pharmacol Ther. 2018;34(8):557-564. 19. Kojima T, Nagata T, Kudo H, et al. The Effects of High Molecular Weight Hyaluronic Acid Eye Drop Application in Environmental Dry Eye Stress Model Mice. Int J Mol Sci. 2020;21(10):3516. Published 2020 May 15. 20. Ehrenberg M, Zolotariov E, Loeb E, Poliansky V, Levy A. Combining Sodium Hyaluronate and Polyvinylpyrrolidone Therapies for the Rabbit Cornea: A New Approach to Relief of the Human Dry Eye Syndrome. Curr Eye Res. 2015;40(9):913-922. 21. Otto S, Roth HW. Wirksamkeit und Verträglichkeit eines Polyvidon-Präparates bei Behandlung von Benetzungsstörungen [Effectiveness and tolerance of a polyvidon substance in treatment of dry eye syndromes]. Klin Monbl Augenheilkd. 1996;209(6):362-367. 22. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312-334. 23. Guillon M, Maissa C, Wong S. Symptomatic relief associated with eyelid hygiene in anterior blepharitis and MGD. Eye Contact Lens. 2012;38(5):306-312. 24. Serge Doan. Clinical Ophthalmology. January 10, 2012. Bichat Hospital and Foundation. Paris, France. 25. Data on File. Laboratoires Théa.